SAN Sanofi

Online availability of Sanofi’s half-year financial report for 2021

Online availability of Sanofi’s half-year financial report for 2021

Online availability of Sanofi’s half-year financial report for 2021



PARIS – July 29, 2021 - Sanofi announces that its half-year financial report for the period ending June 30, 2021 is now available and has been filed with the French market regulator Autorité des marchés financiers (AMF) and submitted to the U.S. Securities and Exchange Commission (SEC) under form 6-K.

This document may be found on the company’s corporate website: and downloaded from the “Investors” page, under the heading “Regulated Information in France”.

About Sanofi 

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. 

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. 

Media Relations Contacts  

Ashleigh Koss

Tel: +1 (908) 205-2572

Sandrine Guendoul

Tel.: +33 (0)6 25 09 14 25

Nicolas Kressmann

Tel.: +1 (732) 532-5318

Investor Relations Contacts Paris 

Eva Schaefer-Jansen 

Arnaud Delepine 

Nathalie Pham 

Investor Relations Contacts North America 

Felix Lauscher 

Fara Berkowitz 

Suzanne Greco  

Tel.: +33 (0)1 53 77 45 45  

 

 

Attachment



EN
29/07/2021

Underlying

SANSanofi

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE
Free
SAN SANOFI

Sanofi - Combined General Meeting of April 29, 2026 - Availability of ...

Sanofi - Combined General Meeting of April 29, 2026 - Availability of Preparatory documents   COMBINED GENERAL MEETING OF APRIL 29, 2026 AVAILABILITY OF PREPARATORY DOCUMENTS The Company’s shareholders are invited to attend the Combined General Meeting to be held on Wednesday April 29, 2026 at 2:30 p.m. (CET) at the Palais des Congrès – Amphithéâtre Bleu – 2, place de la Porte Maillot – 75017 Paris. The notice of meeting (avis de réunion), including the agenda and the draft resolutions as well as the terms and conditions for participating and voting in the meeting, was published on the ...

April 8, 2026 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Sanofi - Assemblée Générale Mixte du 29 avril 2026 - Mise à dispositio...

Sanofi - Assemblée Générale Mixte du 29 avril 2026 - Mise à disposition des documents préparatoires ASSEMBLÉE GÉNÉRALE MIXTE DU 29 AVRIL 2026 MODALITÉS DE MISE À DISPOSITION OU DE CONSULTATION DES DOCUMENTS PRÉPARATOIRES Les actionnaires de la Société sont invités à participer à l’assemblée générale mixte qui se tiendra le mercredi 29 avril 2026 à 14 h 30 au Palais des Congrès – Amphithéâtre Bleu - 2, place de la Porte Maillot – 75017 Paris. L’avis de réunion, comportant l’ordre du jour et les projets de résolutions ainsi que les conditions et modalités de participation et de vote à l’as...

April 8, 2026 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Press Release: Sanofi’s lunsekimig met primary and key secondary endp...

Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP  The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate-to-severe asthma regardless of biomarker status  The DUET phase 2a study met its primary and key secondary endpoints in chronic rhinosinusitis with nasal polyps, reinforcing lunsekimig’s potential as a respiratory treatmentThe exploratory VELVET phase 2b study did ...

April 7, 2026 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Communiqué de presse: Le lunsekimig de Sanofi a atteint les critères d...

Communiqué de presse: Le lunsekimig de Sanofi a atteint les critères d’évaluation principal et secondaires clés dans les études respiratoires de phase 2 dans l’asthme et la rhinosinusite chronique avec polypose nasale Le lunsekimig de Sanofi a atteint les critères d’évaluation principal et secondaires clés dans les études respiratoires de phase 2 dans l’asthme et la rhinosinusite chronique avec polypose nasale L’étude de phase 2b AIRCULES a atteint son critère d’évaluation principal et ses critères d’évaluation secondaires clés dans l’asthme modéré à sévère, quel que soit le statut des bio...

April 7, 2026 1 EN
 PRESS RELEASE
Free
SAN SANOFI

Press Release: Sanofi’s Rezurock approved in the EU to treat chronic g...

Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medicine for patients with limited treatment options Paris, March 31, 2026. The European Commission has granted a conditional marketing authorisation for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (GVHD) in adults and in children aged 12 years and older with a body weight o...

March 31, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch